Overview of pathogenic mechanisms of mutant calreticulin (CALR) in myeloproliferative neoplasms (MPN) and potential ways to target the mutant calreticulin neoantigen by therapeutic monoclonal antibodies (mAb). This evidence concerns the gene CALR and myeloproliferative disorder.